Home > Research > Publications & Outputs > Neuroprotective role of (Val8)GLP-1-Glu-PAL in ...

Research

Electronic data

Links

Text available via DOI:

View graph of relations

Neuroprotective role of (Val8)GLP-1-Glu-PAL in an in vitro model of Parkinson’s disease

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Neuroprotective role of (Val8)GLP-1-Glu-PAL in an in vitro model of Parkinson’s disease. / Li, Lin; Liu, Ke; Holscher, Christian et al.
In: Neural Regeneration Research, Vol. 11, No. 2, 2016, p. 326-331.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Li, L, Liu, K, Holscher, C, Li, G & Liu, Y-Z 2016, 'Neuroprotective role of (Val8)GLP-1-Glu-PAL in an in vitro model of Parkinson’s disease', Neural Regeneration Research, vol. 11, no. 2, pp. 326-331. https://doi.org/10.4103/1673-5374.177742

APA

Li, L., Liu, K., Holscher, C., Li, G., & Liu, Y-Z. (2016). Neuroprotective role of (Val8)GLP-1-Glu-PAL in an in vitro model of Parkinson’s disease. Neural Regeneration Research, 11(2), 326-331. https://doi.org/10.4103/1673-5374.177742

Vancouver

Li L, Liu K, Holscher C, Li G, Liu Y-Z. Neuroprotective role of (Val8)GLP-1-Glu-PAL in an in vitro model of Parkinson’s disease. Neural Regeneration Research. 2016;11(2):326-331. Epub 2016 Mar 16. doi: 10.4103/1673-5374.177742

Author

Li, Lin ; Liu, Ke ; Holscher, Christian et al. / Neuroprotective role of (Val8)GLP-1-Glu-PAL in an in vitro model of Parkinson’s disease. In: Neural Regeneration Research. 2016 ; Vol. 11, No. 2. pp. 326-331.

Bibtex

@article{ca02d4a164af4c04b358bed73d78867c,
title = "Neuroprotective role of (Val8)GLP-1-Glu-PAL in an in vitro model of Parkinson{\textquoteright}s disease",
abstract = "The growth factor glucagon-like peptide-1 (GLP-1) is neuroprotective in several animal models of neurodegeneration. Here, we analyzed the neuroprotective effects of a novel protease-resistant GLP-1 analogue, (Val 8 )GLP-1-Glu-PAL, which has advantages over older analogues, such as improvement of hippocampal neurogenesis, glucose homeostasis, and insulin secretion. We established an in vitro model of Parkinson's disease using the mitochondrial stressor rotenone in primary cultured mouse neurons pretreated with (Val 8 )GLP-1-Glu-PAL. (Val 8 )GLP-1-Glu-PAL alone did not affect neuronal viability, but prevented the rotenone-induced reduction in cell viability in a dose-dependent manner. In addition, (Val 8 )GLP-1-Glu-PAL pretreatment prevented rotenone-induced proapoptotic changes manifesting as downregulation of procaspase-3 and Bcl-2 and upregulation of cleaved caspase-3. These results demonstrate that the novel agent (Val 8 )GLP-1-Glu-PAL shows promise as a drug treatment for Parkinson's disease.",
author = "Lin Li and Ke Liu and Christian Holscher and Guanglai Li and Yue-Ze Liu",
year = "2016",
doi = "10.4103/1673-5374.177742",
language = "English",
volume = "11",
pages = "326--331",
journal = "Neural Regeneration Research",
issn = "1673-5374",
publisher = "Editorial Board of Neural Regeneration Research",
number = "2",

}

RIS

TY - JOUR

T1 - Neuroprotective role of (Val8)GLP-1-Glu-PAL in an in vitro model of Parkinson’s disease

AU - Li, Lin

AU - Liu, Ke

AU - Holscher, Christian

AU - Li, Guanglai

AU - Liu, Yue-Ze

PY - 2016

Y1 - 2016

N2 - The growth factor glucagon-like peptide-1 (GLP-1) is neuroprotective in several animal models of neurodegeneration. Here, we analyzed the neuroprotective effects of a novel protease-resistant GLP-1 analogue, (Val 8 )GLP-1-Glu-PAL, which has advantages over older analogues, such as improvement of hippocampal neurogenesis, glucose homeostasis, and insulin secretion. We established an in vitro model of Parkinson's disease using the mitochondrial stressor rotenone in primary cultured mouse neurons pretreated with (Val 8 )GLP-1-Glu-PAL. (Val 8 )GLP-1-Glu-PAL alone did not affect neuronal viability, but prevented the rotenone-induced reduction in cell viability in a dose-dependent manner. In addition, (Val 8 )GLP-1-Glu-PAL pretreatment prevented rotenone-induced proapoptotic changes manifesting as downregulation of procaspase-3 and Bcl-2 and upregulation of cleaved caspase-3. These results demonstrate that the novel agent (Val 8 )GLP-1-Glu-PAL shows promise as a drug treatment for Parkinson's disease.

AB - The growth factor glucagon-like peptide-1 (GLP-1) is neuroprotective in several animal models of neurodegeneration. Here, we analyzed the neuroprotective effects of a novel protease-resistant GLP-1 analogue, (Val 8 )GLP-1-Glu-PAL, which has advantages over older analogues, such as improvement of hippocampal neurogenesis, glucose homeostasis, and insulin secretion. We established an in vitro model of Parkinson's disease using the mitochondrial stressor rotenone in primary cultured mouse neurons pretreated with (Val 8 )GLP-1-Glu-PAL. (Val 8 )GLP-1-Glu-PAL alone did not affect neuronal viability, but prevented the rotenone-induced reduction in cell viability in a dose-dependent manner. In addition, (Val 8 )GLP-1-Glu-PAL pretreatment prevented rotenone-induced proapoptotic changes manifesting as downregulation of procaspase-3 and Bcl-2 and upregulation of cleaved caspase-3. These results demonstrate that the novel agent (Val 8 )GLP-1-Glu-PAL shows promise as a drug treatment for Parkinson's disease.

U2 - 10.4103/1673-5374.177742

DO - 10.4103/1673-5374.177742

M3 - Journal article

VL - 11

SP - 326

EP - 331

JO - Neural Regeneration Research

JF - Neural Regeneration Research

SN - 1673-5374

IS - 2

ER -